# A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

Source: https://onco.cc/key-papers/paper-krijgsman-blueprint-subtyping-breast-cancer-res-treat-2012/  
OnCo record `paper-krijgsman-blueprint-subtyping-breast-cancer-res-treat-2012` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The development of the 80-gene BluePrint profile, which sorts breast cancers into three biological types that differed in response to chemotherapy before surgery.

## Summary

The 80-gene profile classified tumours as luminal-type, HER2-type or basal-type. In the neoadjuvant cohort, 56 per cent of patients in the basal-type group and 50 per cent in the HER2-type group had a pathological complete response.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Breast Cancer Research and Treatment
- Year: 2012
- DOI: 10.1007/s10549-011-1683-z
- Authors: Krijgsman O, Roepman P, Zwart W, et al.
- Findings: Pathological complete response 56% in basal-type and 50% in HER2-type tumours.
- What it means: Gene activity can refine the subtype that standard receptor staining gives.
- Caveats: Development study by the maker's scientists.

## Sources

- Krijgsman et al., Breast Cancer Res Treat 2012: https://doi.org/10.1007/s10549-011-1683-z
- PubMed: https://pubmed.ncbi.nlm.nih.gov/21814749/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/)
- drugs: [BluePrint](https://onco.cc/drugs/blueprint/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-krijgsman-blueprint-subtyping-breast-cancer-res-treat-2012.json